Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. (CHRS) on February 7, 2022, covering events occurring on February 2 and February 4, 2022. The filing addresses significant changes to the composition of the Company's Board of Directors, including the appointment of a new director, the resignation of a long-serving director, and the reclassification of an existing director to balance board classes.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial information disclosed relates to director compensation arrangements:
- Annual Cash Retainer: $50,000 for the new director (Dr. Lee N. Newcomer).
- Committee Retainer: $7,500 annually for service on the Compensation Committee.
- Equity Grant: Option to purchase 54,000 shares of common stock, vesting over three years.
Material Changes
The following material changes to the Board of Directors were reported:
- Board Expansion: The Board size increased from six to seven directors.
- Appointment: Dr. Lee N. Newcomer was appointed as a Class I director and member of the Compensation Committee. He brings extensive experience in medical oncology and healthcare administration, primarily from UnitedHealth Group.
- Resignation: Dr. James I. Healy resigned from the Board effective February 4, 2022, after an eight-year tenure. The resignation was not due to any disagreement with the Company.
- Reclassification: Director Mark D. Stolper was reclassified from Class III to Class II to achieve a balanced distribution of director terms across the three classes.
Outlook, Risks, and Management Commentary
Management commentary focuses on the strategic rationale for the new appointment, citing Dr. Newcomer's background in the healthcare sector as a key asset. The filing explicitly states that Dr. Healy's departure was amicable and unrelated to operational disagreements. No new risks, contingencies, or unusual items were disclosed in this report. The Company expects to enter into a standard indemnification agreement with Dr. Newcomer.
Investor Verification Checklist
- Verify the impact of the Board composition changes on the Company's strategic direction and governance.
- Review the Company's Definitive Proxy Statement (Schedule 14A) for full details on the Non-Employee Director Compensation policy.
- Confirm the vesting schedule and exercise price of the 54,000 stock options granted to Dr. Newcomer.
- Monitor future filings for the election of Dr. Newcomer at the 2024 annual meeting of stockholders.